Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
allergan
7
×
biotech
eli lilly
7
×
fda
7
×
life sciences
national blog main
national top stories
boston blog main
boston top stories
clinical trials
national
new york blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
bristol-myers squibb
europe blog main
glaxosmithkline
ipo
biohaven
black diamond therapeutics
cancer
What
fda
bio
drugs
roundup
won
black
class
companies
days
diamond’s
drug
migraine
new
notes
treatment
adults
airport
alkermes
allergan
annual
antipsychotic
apocalypse
appetite
approval
approved
arguments
august
beds
benefits
big
biotech
bread
busy
butter
buyout
cancer
cash
caveats
celgene
commercialized
Language
unset
Current search:
fda
×
" eli lilly "
×
allergan
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More